1. Home
  2. WOLF vs CGEM Comparison

WOLF vs CGEM Comparison

Compare WOLF & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

HOLD

Current Price

$31.12

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$15.99

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOLF
CGEM
Founded
1987
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
WOLF
CGEM
Price
$31.12
$15.99
Analyst Decision
Hold
Strong Buy
Analyst Count
2
12
Target Price
$27.50
★ $33.45
AVG Volume (30 Days)
★ 2.1M
1.2M
Earning Date
10-28-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $1,385,982,000.00
N/A
Revenue This Year
$14.87
N/A
Revenue Next Year
$4.07
$280.38
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 19.00
N/A
52 Week Low
$13.49
$6.50
52 Week High
$80.82
$23.19

Technical Indicators

Market Signals
Indicator
WOLF
CGEM
Relative Strength Index (RSI) 59.39 37.50
Support Level $15.33 $13.76
Resistance Level $35.18 $16.31
Average True Range (ATR) 1.89 1.26
MACD 0.76 -0.27
Stochastic Oscillator 70.21 22.72

Price Performance

Historical Comparison
WOLF
CGEM

About WOLF Wolfspeed Inc.

Wolfspeed Inc is an innovator of wide bandgap semiconductors, focused on silicon carbide materials and devices for power applications. Its product families include silicon carbide materials and power devices. Its products are targeted for various applications in the Automotive domain, including electric vehicles and fast charging, as well as existing and emerging applications in the Industrial & Energy domain such as AI data centers, grid modernization and renewable energy and storage as well as aerospace and defense. The company also use contract manufacturers, some of which include captive lines, for certain products and aspects of product fabrication, assembly and packaging. The company has one reportable segment. Majority of revenue comes from United States followed by Hong Kong.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: